Soleo Health

Overview

Soleo Health is a national specialty pharmacy and alternate-site infusion provider for complex therapies administered in the home, ambulatory infusion centers, and other alternate sites of care. Court Square Capital Partners and WindRose Health Investors completed a $1.1B recap in February 2025, replacing prior sponsor H.I.G. Capital. The operating model combines limited-distribution pharmacy access, therapy-specific clinical support, reimbursement execution, and site-of-care coordination.

Soleo is NOT a high-volume retail specialty pharmacy, an oncology specialist, a stand-alone hub, or a PBM-owned dispensing operation. It is most useful when a product needs more than dispense-only specialty pharmacy capability — Soleo operates 28 pharmacy locations with 50-state licensure plus 30+ ambulatory infusion suites, with a clinical model built around specialty pharmacists, registered nurses, reimbursement specialists, patient care ambassadors, and the SoleMetrics outcomes program.

Specialty Pharmacy Capability Model

The framework below standardizes how Rx Almanac evaluates specialty-pharmacies capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Soleo Health is evaluated as national specialty pharmacy and alternate-site infusion provider for complex therapies administered in the home, ambulatory infusion centers, and other alternate sites of care.

Capability	Buyer should compare	Soleo Health readout
Specialty dispensing and channel access	Licensed dispensing footprint, payer network access, LDD participation, referral capture, and ability to serve the target patient geography.	Major fulfillment handoff. Soleo reports 28 pharmacy locations, pharmacy licensure in 50 states, and national nursing coverage.
Benefits, PA, and reimbursement support	Benefit investigation, PA support, appeals coordination, copay/PAP routing, and reimbursement troubleshooting at the pharmacy edge.	Major coverage workflow. Reimbursement specialists are part of the interdisciplinary care model; confirm therapy-specific SLAs in RFP.
Clinical therapy management and adherence	Pharmacist counseling, disease-specific protocols, refill outreach, injection training, persistence programs, and clinical escalation.	Major engagement model. Soleo is built around complex specialty pharmacy plus home and alternate-site infusion, not basic retail dispensing.
Cold chain, REMS, and complex handling	Temperature control, REMS certification, hazardous/controlled-substance handling, biologics, CGT, and other special distribution requirements.	Documented strength. Recent manufacturer-channel wins in immunoglobulin and hemophilia signal fit for complex biologic therapies.
Manufacturer data and outcomes reporting	Status feeds, dispense data, adherence/outcomes reporting, inventory visibility, and reporting cadence suitable for launch governance.	Differentiator to diligence. SoleMetrics gives Soleo a public outcomes-program story, but buyers should define exact data fields, cadence, and escalation ownership.
Site-of-care, infusion, or health-system coordination	Home infusion, ambulatory infusion, provider-office coordination, health-system capture, and buy-and-bill support where relevant.	Major site-of-care coordination. Soleo operates more than 30 infusion suites and centers and continues to add or relocate AIC capacity in growth markets.

Buyer Fit

• Evaluation trigger: Include Soleo when a specialty biologic launch needs combined limited-distribution pharmacy access, ambulatory infusion suites, home-nursing coverage, and SoleoRare rare-disease workflows in one partner.
• Profile signal: Independent national specialty infusion platform with 28 pharmacy locations, 50-state licensure, 30+ ambulatory infusion suites, SoleoRare rare-disease brand, and SoleMetrics outcomes program; Court Square + WindRose PE backing since Feb 2025.
• Best-fit therapies: Rare disease, immunoglobulin, hemophilia, autoimmune, neurology, gastroenterology, anti-infective, and other specialty biologic therapies that need pharmacy support plus infusion or clinical coordination.
• Less ideal fit: Oral specialty products that can be handled through a conventional limited-distribution network without infusion, nursing, or site-of-care complexity; high-volume oncology launches that need oncology-specialist scale.
• Commercial fit: Pricing is undisclosed; assume RFP-led scope with data feeds, AIC market coverage, home-nursing capacity, and hub coordination defined in the SOW.
• Commercial diligence: Payer access, local AIC availability, home-nursing capacity, time-to-start, LDD onboarding experience, data-feed maturity, and coordination with the brand hub or field reimbursement team.

Differentiators

• Specialty pharmacy plus infusion model: Soleo can support both dispensing and administration workflows, which matters when channel access and site-of-care execution are linked.
• Rare disease focus: SoleoRare gives manufacturers a dedicated rare disease specialty pharmacy structure rather than a generic complex-therapy queue.
• Outcomes orientation: SoleMetrics supports a clearer evidence and reporting narrative for payers, manufacturers, and health systems.
• National licensing with local care sites: The footprint combines 50-state pharmacy licensure with ambulatory infusion suites and home-infusion support.
• Independent alternative: Soleo offers a non-PBM-owned option for manufacturers comparing independent specialty infusion providers against vertically integrated pharmacy organizations.

RFP Questions

• Which locations, infusion suites, home-nursing markets, and payer contracts are actually available for this product at launch?
• What experience does the team have with the target indication, drug type, route of administration, and handling requirements?
• How will Soleo coordinate referrals, benefit investigation, PA / reauthorization, shipment, administration, adverse-event escalation, and discontinuation reporting?
• Which data fields will the manufacturer receive for referral status, start, abandonment, persistence, outcomes, inventory, and exceptions?
• How will Soleo work with the hub, prescribers, field reimbursement managers, patient services teams, and any existing limited-distribution network?
• What volume, staffing, and geography assumptions must be true for the proposed service levels to hold?

Recent Activity

• 2026-05 - Current Soleo materials emphasize SoleoRare, rare-disease commercial teams, HEOR / RWE support, authorized specialty-pharmacy roles, and expanding ambulatory infusion capacity.

• 2026-04 SoleoRare launch: Soleo introduced a dedicated rare disease specialty pharmacy brand for rare, ultra-rare, and orphan disease patients, with patient care, access, and commercial teams organized around that segment.

• 2026-04 QIVIGY authorization: Soleo was selected as an authorized specialty pharmacy for Kedrion Biopharma’s QIVIGY for adult primary humoral immunodeficiency.

• 2026-04 ambulatory infusion expansion: Soleo opened new AIC capacity in Austin (with pediatric rooms) and Louisville, complementing 2026 relocations in Denver and the St. Louis metro.

• 2025-12: Jody Thompson joined as SVP of Business Development, Rare Disease ahead of the SoleoRare launch.

• 2025-02: Court Square Capital Partners and WindRose Health Investors completed a $1.1B recap of Soleo Health from H.I.G. Capital.